Grandfield & Dodd, LLC Regeneron Pharmaceuticals, Inc. Transaction History

Grandfield & Dodd, LLC

  • $1.49 Billion
  • Q2 2024

A detailed history of Grandfield & Dodd, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Grandfield & Dodd, LLC holds 32,336 shares of REGN stock, worth $32.8 Million. This represents 2.28% of its overall portfolio holdings.

Number of Shares
32,336
Previous 32,277 0.18%
Holding current value
$32.8 Million
Previous $31.1 Million 9.4%
% of portfolio
2.28%
Previous 2.07%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024
BUY
$883.2 - $1071.19 $52,108 - $63,200
59 Added 0.18%
32,336 $34 Million
Q1 2024

May 03, 2024
BUY
$902.69 - $993.35 $67,701 - $74,501
75 Added 0.23%
32,277 $31.1 Million
Q4 2023

Jan 31, 2024
SELL
$775.18 - $881.7 $31,007 - $35,268
-40 Reduced 0.12%
32,202 $28.3 Million
Q3 2023

Oct 25, 2023
BUY
$692.45 - $844.37 $528,339 - $644,254
763 Added 2.42%
32,242 $26.5 Million
Q2 2023

Aug 07, 2023
BUY
$700.03 - $830.35 $387,816 - $460,013
554 Added 1.79%
31,479 $22.6 Million
Q1 2023

Apr 28, 2023
BUY
$680.49 - $826.97 $305,540 - $371,309
449 Added 1.47%
30,925 $25.4 Million
Q4 2022

Jan 20, 2023
BUY
$705.89 - $766.39 $144,001 - $156,343
204 Added 0.67%
30,476 $0
Q3 2022

Nov 03, 2022
BUY
$573.97 - $724.32 $572,822 - $722,871
998 Added 3.41%
30,272 $20.9 Million
Q2 2022

Aug 01, 2022
BUY
$548.35 - $738.84 $274,175 - $369,420
500 Added 1.74%
29,274 $17.3 Million
Q1 2022

Apr 19, 2022
BUY
$595.12 - $698.43 $581,432 - $682,366
977 Added 3.51%
28,774 $20.1 Million
Q4 2021

Feb 08, 2022
BUY
$543.48 - $670.97 $959,785 - $1.18 Million
1,766 Added 6.78%
27,797 $17.6 Million
Q3 2021

Oct 28, 2021
BUY
$574.03 - $680.96 $2.52 Million - $2.99 Million
4,395 Added 20.31%
26,031 $15.8 Million
Q2 2021

Jul 28, 2021
BUY
$472.8 - $558.54 $1.45 Million - $1.72 Million
3,074 Added 16.56%
21,636 $12.1 Million
Q1 2021

Apr 22, 2021
BUY
$446.73 - $548.2 $360,511 - $442,397
807 Added 4.55%
18,562 $8.78 Million
Q4 2020

Jan 29, 2021
BUY
$478.3 - $607.98 $518,955 - $659,658
1,085 Added 6.51%
17,755 $8.58 Million
Q3 2020

Nov 03, 2020
BUY
$544.75 - $658.21 $4,902 - $5,923
9 Added 0.05%
16,670 $9.33 Million
Q2 2020

Jul 24, 2020
SELL
$493.32 - $643.92 $208,674 - $272,378
-423 Reduced 2.48%
16,661 $10.4 Million
Q1 2020

May 14, 2020
BUY
$336.18 - $494.43 $376,185 - $553,267
1,119 Added 7.01%
17,084 $8.34 Million
Q4 2019

Feb 07, 2020
BUY
$274.13 - $376.51 $643,657 - $884,045
2,348 Added 17.24%
15,965 $6 Million
Q3 2019

Oct 30, 2019
BUY
$273.46 - $318.39 $552,115 - $642,829
2,019 Added 17.41%
13,617 $3.78 Million
Q2 2019

Jul 29, 2019
BUY
$299.6 - $414.82 $784,952 - $1.09 Million
2,620 Added 29.18%
11,598 $3.63 Million
Q1 2019

Apr 26, 2019
BUY
$372.08 - $439.57 $105,298 - $124,398
283 Added 3.25%
8,978 $3.69 Million
Q4 2018

Feb 12, 2019
BUY
$335.82 - $403.04 $511,118 - $613,426
1,522 Added 21.22%
8,695 $3.25 Million
Q3 2018

Nov 02, 2018
BUY
$351.14 - $408.51 $465,962 - $542,092
1,327 Added 22.7%
7,173 $2.9 Million
Q2 2018

Jul 27, 2018
BUY
$284.6 - $344.99 $967,924 - $1.17 Million
3,401 Added 139.1%
5,846 $2.02 Million
Q1 2018

May 04, 2018
BUY
$315.82 - $393.78 $224,548 - $279,977
711 Added 41.0%
2,445 $842,000
Q4 2017

Feb 06, 2018
BUY
$358.63 - $469.95 $31,200 - $40,885
87 Added 5.28%
1,734 $652,000
Q3 2017

Nov 03, 2017
BUY
$431.38 - $504.0 $710,482 - $830,088
1,647
1,647 $736,000

Others Institutions Holding REGN

# of Institutions
1,464
Shares Held
84.4M
Call Options Held
907K
Put Options Held
1.3M
View Full List

About REGENERON PHARMACEUTICALS, INC.

REGN Quotes by TradingView
  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $109B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Grandfield & Dodd, LLC Portfolio

Follow Grandfield & Dodd, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grandfield & Dodd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Grandfield & Dodd, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email